Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells
Small · 2023
DOI: 10.1002/smll.202206503 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2023. Verfasst von Shuang Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Bionanomaterials & …. Hauptthemen laut MEDLINE: Neoplasms, Hyperthermia, Induced. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: National Basic Research Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Cancer stem cells (CSCs), a type of cell with self‐renewal, unlimited proliferation, and insensitivity to common physical and chemical factors, are the key to cancer metastasis, recurrence, and chemo‐resistance. Available CSCs inhibition strategies are mainly based on small molecule drugs, yet are limited by their off‐target toxicity. The link between CSCs and non‐CSCs interconversion is difficult to sever. In this work, a nanotherapeutic strategy based on MnO x ‐loaded polydopamine (MnO x /PDA) nanobombs with chemodynamic, photodynamic, photothermal and biodegradation properties to inhibit CSCs and non‐CSCs concurrently is reported. The MnO x /PDA nanobombs can directly disrupt the microenvironment and tumorigenic capacity of CSCs by generating hyperthermia, oxidative stress and alleviating hypoxia. The markers of CSCs are subsequently downregulated, leading to the clearance of CSCs. Meanwhile, the synergistic therapy mediated by MnO x /PDA nanobombs can directly ablate the bulk tumor cells, thus cutting off the supply of CSCs transformation. For tumor targeting, MnO x /PDA is coated with macrophage membrane. The final tumor inhibition rate of the synergistic therapy is 70.8% in colorectal cancer (CRC) model. Taken together, the present work may open up the exploration of nanomaterial‐based synergistic therapy for the simultaneous elimination of therapeutically resistant CSCs and non‐CSCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Bionanomaterials & Translational Engineering Laboratory, Beijing Key Laboratory of Biopro…
- Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100050, China.
ORCID-Profile: Huiyu Liu
Förderung
- National Basic Research Program of China
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Zhang, T., Li, S., Wu, Q., Wang, K., Xu, X., Lu, M., Shao, R., Zhao, W., & Liu, H. (2023). Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells. Small. https://doi.org/10.1002/smll.202206503
Vancouver
Liu S, Zhang T, Li S, Wu Q, Wang K, Xu X, et al. Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells. Small. 2023. doi:10.1002/smll.202206503
BibTeX
@article{Liu2023,
author = {Liu, Shuang and Zhang, Tianshu and Li, Shanshan and Wu, Qingyuan and Wang, Kexin and Xu, Xican and Lu, MingZhu and Shao, Rongguang and Zhao, Wuli and Liu, Huiyu},
title = {Biomimetic Nanobomb for Synergistic Therapy with Inhibition of Cancer Stem Cells},
journal = {Small},
year = {2023},
doi = {10.1002/smll.202206503}
}
EUVIMED